Results 21 to 30 of about 352 (104)

Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature

Cancer Medicine
Chemotherapy‐induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care.
Gerald A. Soff, Hanny Al‐Samkari, Avi Leader, Melissa Eisen, Hossam Saad   +4 more
doaj   +1 more source

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?

Folia Medica Indonesiana, 2016
Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management
Jefri Pratama Susanto
doaj   +1 more source

The role of romiplostim for pediatric patients with immune thrombocytopenia

Therapeutic Advances in Hematology, 2020
The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors used to treat immune thrombocytopenia (ITP) in children and adults.
Hanny Al-Samkari, Rachael F. Grace, David J. Kuter   +2 more
doaj   +1 more source

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim

Hematology Reports, 2011
Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and is now accepted that the disorder
Efthymia Vlachaki, Vaia Papageorgiou, Filippos Klonizakis, Maria Spandonidou, Sofia Chisan, Evaggelia Vetsiou, Elissavet Ioannidou   +6 more
doaj   +1 more source

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity

Pharmaceuticals, 2023
Immune thrombocytopenia (ITP) treatment has evolved recently. However, none of the treatments have only benefits without drawbacks. This study aimed to compare the clinical outcomes and adverse drug patterns of Eltrombopag, Romiplostim, Prednisolone ...
Eman Mostafa Hamed, Ahmed R. N. Ibrahim, Mohamed Hussein Meabed, Ahmed M. Khalaf, Doaa Mohamed El Demerdash, Marwa O. Elgendy, Haitham Saeed, Heba F. Salem, Hoda Rabea   +8 more
doaj   +1 more source

Efficacy and Safety of rhIL‐11 in the Treatment of Cancer Therapy‐Induced Thrombocytopenia: A Multicenter Retrospective Study

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Objective This real‐world study aimed to investigate the cancer therapy‐induced thrombocytopenia (CTIT) profile and evaluate the efficacy and safety of recombinant human interleukin‐11 (rhIL‐11) in its management. Methods Retrospective analysis included 12,431 CTIT patients treated with rhIL‐11 across 58 Chinese centers (July 2023–June 2024 ...
Yingmei Wen, Yi Dong, Yingge Li, Jinxiong Xia, Zheming Liu, Yuanyuan Wang, Ruibin Li, Ming Wang, Bin Xu, Dongling Tang, Lulu Chen, Huibo Zhang, Qibin Song, Yi Yao   +13 more
wiley   +1 more source

Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia

BMC Cancer
Objective This study retrospectively compared the efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in managing chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumours, aiming to provide valuable evidence ...
Yu Cheng, Juan Wei, Fang Zhu, Liang Xuan, Yuan Li, Lei Meng, Chuandong Zhu, Huihui Zhao   +7 more
doaj   +1 more source

Real‐World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis

European Journal of Haematology, Volume 117, Issue 1, Page 174-185, July 2026.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real‐world evidence. Methods A systematic search was conducted following the PRISMA 2020 guidelines.
M. L. Lozano, D. Valcarcel
wiley   +1 more source

Efficacy of romiplostim therapy for hematological toxicity in patients with solid tumors

Клинический разбор в общей медицине
Background. Romiplostim is a medicinal product belonging to the group of thrombopoietin receptor agonists that has shown its efficacy and safety in treatment of immune thrombocytopenia. The number of studies focused on the efficacy of this group of drugs
Anna K. Vaskovskaia, Radion V. Tarnovsky
doaj   +1 more source

Trilineage hematopoietic recovery with romiplostim in a child with down syndrome and aplastic anemia: A case report and review of literature

Pediatric Hematology Oncology Journal
Background: Severe aplastic anemia (SAA) associated with Down syndrome (DS) is a rare hematological disease with only a few cases reported in the literature.
Dima Abla, Huda Al Habsi, Nasser Al Rahbi, Alyaa Al Mughairy   +3 more
doaj   +1 more source